Acyl-CoA synthetase 4 (ACSL4) inhibitory compound
US12280059B2 · kind B2 · utility
0Cited by
1References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 20, 2020 |
| Grant date | Apr 22, 2025 |
| Priority date | — |
| Expiry date | Jul 21, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A new compound of formula A for the treatment of aggressive and/or resistant tumors expressing acyl-CoA synthetase 4 (ACSL4) and/or depending on steroids action. More particularly, the compound of the present invention inhibits tumor growth in ACSL4-expressing breast and prostate cancers, inhibits steroid synthesis and sensitizes cells towards chemotherapeutic and hormone therapy agents. Pharmaceutical compositions comprising the ACSL4-inhibitory compound of the invention, pharmaceutical combinations thereof with other anticancer agents and use in therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.